Macrophages and angiogenesis in rheumatic diseases

Vascular Cell

Domenico Ribatti²  Francesco Paolo Cantatore¹  Tiziana Annese²  Nicola Maruotti¹ 

[1] Rheumatology Clinic, Department of Medical and Surgical Sciences, University of Foggia Medical School- Ospedale “ D’Avanzo”, Foggia, Italy;Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Piazza Giulio Cesare, 11, Policlinico, 70124, Bari, Italy

关键词: Vasculitides;    Macrophage;    Connectivities;    Arthritis;    Angiogenesis;   

Others  :  801753
DOI  :  10.1186/2045-824X-5-11

 received in 2013-03-20, accepted in 2013-04-26,  发布年份 2013

【 摘 要 】

Angiogenesis plays a key role in several rheumatic diseases, including rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, systemic sclerosis, systemic lupus erythematosus, and vasculitides. An imbalance between angiogenic inducers and inhibitors seems to be a critical factor in pathogenesis of these diseases. Macrophages promote angiogenesis during rheumatoid arthritis. In addition, macrophages can produce a variety of pro-angiogenic factors that have been associated with the angiogenic response occurring during other rheumatic diseases. Lastly, macrophages could be a target in the treatment of rheumatoid arthritis and other rheumatic diseases. Nevertheless, further studies are needed to better elucidate the exact role of macrophage in angiogenesis in these diseases.

【 授权许可】

   
2013 Maruotti et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Ross JA, Auger MJ: The biology of the macrophage. In The macrophage. 2nd edition. Edited by Nurke B, Lewis CE. Oxford: Oxford University Press; 2002.
• [2]Pollard JW: Trophic macrophages in development and disease. Nat Rev Immunol 2009, 9:259-270.
• [3]Murdoch C, Muthana M, Coffelt SB, Lewis CE: The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008, 8:618-631.
• [4]Mantovani A, Sozzani S, Locati M, Allavena P, Sica A: Macrophage polarization: tumor associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23:549-555.
• [5]Balkwill F, Charles KA, Mantovani A: Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005, 7:211-217.
• [6]Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
• [7]Ribatti D, Vacca A, Dammacco F: The role of the vascular phase in solid tumor growth: a historical review. Neoplasia 1999, 1:293-302.
• [8]Risau W: Mechanisms of angiogenesis. Nature 1997, 386:671-674.
• [9]Patan S, Munn LL, Jain RK: Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. Microvasc Res 1996, 51:260-272.
• [10]Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL: Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 2000, 97:14608-14613.
• [11]Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, Trent JM, Meltzer PS, Hendrix MJ: Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999, 155:739-752.
• [12]Ballara SC, Miotla JM, Paleolog EM: New vessels, new approaches: angiogenesis as a therapeutic target in musculoskeletal disorders. Int J Exp Pathol 1999, 80:235-250.
• [13]Bian XW, Chen JH, Jiang XF, Bai JS, Wang QL, Zhang X: Angiogenesis as an immunopharmacologic target in inflammation and cancer. Int Immunopharmacol 2004, 4:1537-1547.
• [14]Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familletti PC, Pan YC, Olander JV, Connolly DT, Stern D: Vascular permeability factor: a tumor derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990, 172:1535-1545.
• [15]Melder RJ, Koenig GC, Witwer BP, Safabakhsh N, Munn LL, Jain RK: During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 1996, 2:992-997.
• [16]Buckley CD, Amft N, Bradfield PF, Pilling D, Ross E, Arenzana-Seisdedos F, Amara A, Curnow SJ, Lord JM, Scheel-Toellner D, Salmon M: Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J Immunol 2000, 165:3423-3429.
• [17]Buckley CD, Pilling D, Lord JM, Akbar AN, Scheel-Toellner D, Salmon M: Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol 2001, 22:199-204.
• [18]Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, Vlodavsky I: A heparin-binding angiogenic protein – basic fibroblast growth factor – is stored within basement membrane. Am J Pathol 1988, 130:393-400.
• [19]Maruotti N, Cantatore FP, Crivellato E, Vacca A, Ribatti D: Macrophages in rheumatoid arthritis. Histol Histopathol 2007, 22:581-586.
• [20]Okada Y: Proteinases and matrix degradation. In Kelley’s Textbook of Rheumatology. 7th edition. Edited by Harris ED Jr, Budd RC, Firestein GS, etal. Philadelphia: Elsevier Saunders; 2005:63-81.
• [21]Pakozdi A, Amin MA, Haas CS, Martinez RJ, Haines GK 3rd, Santos LL, Morand EF, David JR, Koch AE: Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis. Arthritis Res Ther 2006, 8:R132. BioMed Central Full Text
• [22]Néstor T, Masckauchán H, Kitajewski J: Wnt/frizzled signaling in the vasculature: new angiogenic factors in sight. Physiology 2006, 21:181-188.
• [23]Pereira C, Schaer DJ, Bachli EB, Kurrer MO, Schoedon G: Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10. Arterioscler Thromb Vasc Biol 2008, 28:504-510.
• [24]Kim J, Kim DW, Ha Y, Ihm MH, Kim H, Song K, Lee I: Wnt5a induces endothelial inflammation via beta-catenin-independent signaling. J Immunol 2010, 185:1274-1282.
• [25]Stefater JA 3rd, Lewkowich I, Rao S, Mariggi G, Carpenter AC, Burr AR, Fan J, Ajima R, Molkentin JD, Williams BO, Wills-Karp M, Pollard JW, Yamaguchi T, Ferrara N, Gerhardt H, Lang RA: Regulation of angiogenesis by a non-canonical Wnt-Flt1 pathway in myeloid cells. Nature 2011, 474:511-515.
• [26]Crampton SP, Wu B, Park EJ, Kim JH, Solomon C, Waterman ML, Hughes CC: Integration of the beta-catenin-dependent Wnt pathway with integrin signaling through the adaptor molecule Grb2. PLoS One 2009, 4:e7841.
• [27]Szekanecz Z, Koch AE: Chemokines and angiogenesis. Curr Opin Rheumatol 2001, 13:202-208.
• [28]Szekanecz Z, Gáspár L, Koch AE: Angiogenesis in rheumatoid arthritis. Front Biosci 2005, 10:1739-1753.
• [29]Koch AE: Chemokines and their receptors in rheumatoid arthritis. Arthritis Rheum 2005, 52:710-721.
• [30]Taub DD: C-C chemokines – an overview. In Chemokines in disease. Edited by Koch AE, Strieter RM. Austin: RG Landes Company; 1996:27-54.
• [31]Walz A, Kunkel SL, Strieter RM: C-X-C chemokines – an overview. In Chemokines in disease. Edited by Koch AE, Strieter RM. Austin: RG Landes Company; 1996:1-25.
• [32]Koch AE, Kunkel SL, Harlow LA, Mazarakis DD, Haines GK, Burdick MD, Strieter RM: Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J Clin Invest 1994, 94:1012-1018.
• [33]Walz A, Burgener R, Car B, Baggiolini M, Kunkel SL, Strieter RM: Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J Exp Med 1991, 174:1355-1362.
• [34]Koch AE, Volin MV, Woods JM, Kunkel SL, Connors MA, Harlow LA, Woodruff DC, Burdick MD, Strieter RM: Regulation of angiogenesis by the C-X-C chemokines interleukin-8 and epithelial neutrophil activating peptide-78 in the rheumatoid joint. Arthritis Rheum 2001, 44:31-40.
• [35]Ruth JH, Volin MV, Haines GK III, Woodruff DC, Katschke KJ Jr, Woods JM, Park CC, Morel JC, Koch AE: Fractalkine, a novel chemokine in rheumatoid arthritis and rat adjuvant-induced arthritis. Arthritis Rheum 2001, 44:1568-1581.
• [36]Volin MV, Woods JM, Amin MA, Connors MA, Harlow LA, Koch AE: Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis. Am J Pathol 2001, 159:1521-1530.
• [37]Yamaguchi A, Nozawa K, Fujishiro M, Kawasaki M, Suzuki F, Takamori K, Ogawa H, Takasaki Y, Sekigawa I: CC motif chemokine ligand 13 is associated with rheumatoid arthritis pathogenesis. Mod Rheumatolin press
• [38]Thomas R, Arend WP: Antigen-presenting cells. In Kelley’s Textbook of Rheumatology. 7th edition. Edited by Harris ED Jr, Budd RC, Firestein GS, etal. Philadelphia: Elsevier Saunders; 2005:101-119.
• [39]McInnes IB: Cytokines. In Kelley’s Textbook of Rheumatology. 7th edition. Edited by Harris ED Jr, Budd RC, Firestein GS, etal. Philadelphia: Elsevier Saunders; 2005:379-389.
• [40]Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, Jackman RW, Senger DR, Dvorak HF, Brown LF: Vascular Permeability Factor/Endothelial Growth Factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994, 180:341-346.
• [41]Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C, D’Amore P, Dana R, Wiegand SJ, Streinlein JW: VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004, 113:1040-1050.
• [42]Hamrah P, Chen L, Zhang Q, Dana R: Novel expression of vascular endothelial endothelial growth factor (VEGFR)-3 and VEGF-C on corneal dendritic cells. Am J Pathol 2003, 163:57-68.
• [43]Hamrah P, Chen L, Cursiefen C, Zhang Q, Joyce NC, Dana R: Expression of vascular endothelial endothelial growth factor receptor-3 (VEGFR-3) on monocytic bone marrow-derived cells in the conjunctiva. Exp Eye Res 2004, 79:553-561.
• [44]Chen L, Hamrah P, Cursiefen C, Zhang Q, Pytowski B, Streilein JW, Dana R: Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat Med 2004, 10:813-815.
• [45]Burke B, Giannoudis A, Corke KP, Gill D, Wells M, Ziegler-Heitbroke L, Lewis CE: Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am J Pathol 2003, 163:1233-1243.
• [46]Dineen SP, Lynn KD, Holloway SE, Miller AF, Sullivan JP, Shames DS, Beck AW, Barnett CC, Fleming JB, Brekken RA: Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res 2008, 68:4340-4346.
• [47]Murakami M, Iwai S, Hiratsuka S, Yamauchi M, Nakamura K, Iwakura Y, Shibuya M: Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. Blood 2006, 108:1849-1856.
• [48]Chung ES, Chauhan SK, Jin Y, Nakao S, Hafezi-Moghadam A, van Rooijen N, Zhang Q, Chen L, Dana R: Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands. Am J Pathol 2009, 175:1984-1992.
• [49]Koch AE, Kunkel SL, Burrows JC, Evanoff HL, Haines GK, Pope RM, Strieter RM: Synovial tissue macrophage as a source of the chemotactic cytokine IL-8. J Immunol 1991, 147:2187-2195.
• [50]De Gendt CM, De Clerck LS, Bridts CH, Van Osselaer N, Stevens WJ: Relationship between interleukin-8 and neutrophil adhesion molecules in rheumatoid arthritis. Rheumatol Int 1996, 16:169-173.
• [51]Pickens SR, Volin MV, Mandelin AM 2nd, Kolls JK, Pope RM, Shahrara S: IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol 2010, 184:3233-3241.
• [52]Yoo JK, Kwon H, Khil LY, Zhang L, Jun HS, Yoon JW: Interleukin-18 induces monocyte chemotactic protein-1 production in macrophages through the phosphatidylinositol 3-kinase/Akt and MEK/ERK1/2 pathways. J Immunol 2005, 175:8280-8286.
• [53]Pohlers D, Huber R, Ukena B, Kinne RW: Expression of platelet-derived growth factors C and D in the synovial membrane of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum 2006, 54:788-794.
• [54]Carmi Y, Voronov E, Dotan S, Lahat N, Rahat MA, Fogel M, Huszar M, White MR, Dinarello CA, Apte RN: The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. J Immunol 2009, 183:4705-4714.
• [55]Murdoch C, Muthana M, Lewis CE: Hypoxia regulates macrophage functions in inflammation. J Immunol 2005, 175:6257-6263.
• [56]Hollander AP, Corke KP, Freemont AJ, Lewis CE: Expression of hypoxia-inducible factor 1 alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint. Arthritis Rheum 2001, 44:1540-1544.
• [57]Taylor PC, Miotla JM, Etherington P, Winlove P, Young Y, Paleolog E, Maini RN: VEGF release is associated with hypoxia in inflammatory arthritis. Arthritis Rheum 2000, 43:S296.
• [58]Santos LL, Morand EF: The role of macrophage migration inhibitory factor in the inflammatory response and rheumatoid arthritis. Wien Med Wochenschr 2006, 156:11-18.
• [59]Nishioka K, Ohshima S, Umeshita-Sasai M, Yamaguchi N, Mima T, Nomura S, Murata N, Shimizu M, Miyake T, Yoshizaki K, Suemura M, Kishimoto T, Saeki Y: Enhanced expression and DNA binding activity of two CCAAT/enhancer-binding protein isoforms, C/EBPbeta and C/EBPdelta, in rheumatoid synovium. Arthritis Rheum 2000, 43:1591-1596.
• [60]Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN: Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol 2006, 38:1654-1661.
• [61]Lu YC, Kim I, Lye E, Shen F, Suzuki N, Gerondakis S, Akira S, Gaffen SL, Yeh WC, Ohashi PS: Differential role for c-Rel and C/EBPbeta/delta in TLR-mediated induction of proinflammatory cytokines. J Immunol 2009, 182:7212-7221.
• [62]Litvak V, Ramsey SA, Rust AG, Zak DE, Kennedy KA, Lampano AE, Nykter M, Shmulevich I, Aderem A: Function of C/EBPdelta in a regulatory circuit that discriminates between transient and persistent TLR4-induced signals. Nat Immunol 2009, 10:437-443.
• [63]Chang LH, Huang HS, Wu PT, Jou IM, Pan MH, Chang WC, Wang DD, Wang JM: Role of macrophage CCAAT/enhancer binding protein delta in the pathogenesis of rheumatoid arthritis in collagen-induced arthritic mice. PLoS One 2012, 7:e45378.
• [64]Milner CM, Day AJ: TSG-6: a multifunctional protein associated with inflammation. J Cell Sci 2003, 116:1863-1873.
• [65]Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q, Richmond A, Strieter R, Dey SK, DuBois RN: CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med 2006, 203:941-951.
• [66]Milner CM, Higman VA, Day AJ: TSG-6: a pluripotent inflammatory mediator? Biochem Soc Trans 2006, 34:446-450.
• [67]Glant TT, Kamath RV, Bárdos T, Gál I, Szántó S, Murad YM, Sandy JD, Mort JS, Roughley PJ, Mikecz K: Cartilage-specific constitutive expression of TSG-6 protein (product of tumor necrosis factor alpha-stimulated gene 6) provides a chondroprotective, but not antiinflammatory, effect in antigen-induced arthritis. Arthritis Rheum 2002, 46:2207-2218.
• [68]Wisniewski HG, Vilcek J: TSG-6: an IL-1/TNF-inducible protein with anti-inflammatory activity. Cytokine Growth Factor Rev 1997, 8:143-156.
• [69]Park YW, Kang YM, Butterfield J, Detmar M, Goronzy JJ, Weyand CM: Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in rheumatoid arthritis. Am J Pathol 2004, 165:2087-2098.
• [70]Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, Hibbert L, Churakova T, Travis M, Vaisberg E, Blumenschein WM, Mattson JD, Wagner JL, To W, Zurawski S, McClanahan TK, Gorman DM, Bazan JF, de Waal Malefyt R, Rennick D, Kastelein RA: IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002, 16:779-790.
• [71]Niedbala W, Cai B, Wei X, Patakas A, Leung BP, McInnes IB, Liew FY: Interleukin 27 attenuates collagen-induced arthritis. Ann Rheum Dis 2008, 67:1474-1479.
• [72]Pickens SR, Chamberlain ND, Volin MV, Mandelin AM 2nd, Agrawal H, Matsui M, Yoshimoto T, Shahrara S: Local expression of interleukin-27 ameliorates collagen-induced arthritis. Arthritis Rheum 2011, 63:2289-2298.
• [73]Haywood L, McWilliams DF, Pearson CI, Gill SE, Ganesan A, Wilson D, Walsh DA: Inflammation and angiogenesis in osteoarthritis. Arthritis Rheum 2003, 48:2173-2177.
• [74]Bonnet CS, Walsh DA: Osteoarthritis, angiogenesis and inflammation. Rheumatology (Oxford) 2005, 44:7-16.
• [75]Szekanecz Z, Koch AE: Mechanism of disease: angiogenesis in inflammatory diseases. Nat Clin Pract Rheumatol 2007, 3:635-643.
• [76]Koch AE, Distler O: Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther 2007, 9:S3.
• [77]Bodolay E, Koch AE, Kim J, Szegedi G, Szekanecz Z: Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. J Cell Mol Med 2002, 6:357-376.
• [78]Cid MC, Hernández-Rodríguez J, Esteban MJ, Cebrián M, Gho YS, Font C, Urbano-Márquez A, Grau JM, Kleinman HK: Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis. Circulation 2002, 106:1664-1671.
• [79]Coll-Vinent B, Vilardell C, Font C, Oristrell J, Hernández-Rodríguez J, Yagüe J, Urbano-Márquez A, Grau JM, Cid MC: Circulating soluble adhesion molecules in patients with giant cell arteritis. Correlation between soluble intercellular adhesion molecule-1 (sICAM-1) concentrations and disease activity. Ann Rheum Dis 1999, 58:189-192.
• [80]Hernández-Rodríguez J, García-Martínez A, Casademont J, Filella X, Esteban MJ, López-Soto A, Fernández-Solà J, Urbano-Márquez A, Grau JM, Cid MC: A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum 2002, 47:29-35.
• [81]Weyand CM, Tetzlaff N, Bjornsson J, Brack A, Younge B, Goronzy JJ: Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum 1997, 40:19-26.
• [82]Lie JT: Histopathologic specificity of systemic vasculitis. Rheum Dis Clin North Am 1995, 21:883-909.
• [83]Weyand CM, Wagner AD, Bjornsson J, Goronzy JJ: Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis. J Clin Invest 1996, 98:1642-1649.
• [84]Nikkari ST, Hoyhtya M, Isola J, Nikkari T: Macrophages contain 92-kd gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. Am J Pathol 1996, 149:1427-1433.
• [85]Kaiser M, Weyand CM, Bjornsson J, Goronzy JJ: Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum 1998, 41:623-633.
• [86]Halacheva K, Gulubova MV, Manolova I, Petkov D: Expression of ICAM-1, VCAM-1, E-selectin and TNF-alpha on the endothelium of femoral and iliac arteries in thromboangiitis obliterans. Acta Histochem 2002, 104:177-184.
• [87]Terai M, Yasukawa K, Narumoto S, Tateno S, Oana S, Kohno Y: Vascular endothelial growth factor in acute Kawasaki disease. Am J Cardiol 1999, 83:337-339.
• [88]Nam EJ, Han SW, Kim SU, Cho JH, Sa KH, Lee WK, Park JY, Kang YM: Association of vascular endothelial growth factor gene polymorphisms with Behcet disease in a Korean population. Hum Immunol 2005, 66:1068-1073.
• [89]Bozoglu E, Dinc A, Erdem H, Pay S, Simsek I, Kocar IH: Vascular endothelial growth factor and monocyte chemoattractant protein-1 in BD patients with venous thrombosis. Clin Exp Rheumatol 2005, 23:S42-S48.
• [90]Erdem H, Pay S, Serdar M, Simşek I, Dinç A, Muşabak U, Pekel A, Turan M: Different ELR (+) angiogenic CXC chemokine profiles in synovial fluid of patients with BD, familiar Mediterranean fever, rheumatoid arthritis, and osteoarthritis. Rheumatol Int 2005, 26:162-167.
• [91]Yacin B, Arda N, Tezel GG, Erman M, Alli N: Expressions of vascular endothelial growth factor and CD34 in oral aphthous lesions of Behcet's disease. Anal Quant Cytol Histol 2006, 28:303-306.
• [92]Jahangier ZN, Jacobs JW, Kraan MC, Wenting MJ, Smeets TJ, Bijlsma JW, Lafeber FP, Tak PP: Pretreatment macrophage infiltration of the synovium predicts the clinical effect of both radiation synovectomy and intra-articular glucocorticoids. Ann Rheum Dis 2006, 65:1286-1292.
• [93]Jang CH, Choi JH, Byun MS, Jue DM: Chloroquin inhibits production of TNFalpha, interleukin-1 and interleukin-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. Rheumatology 2006, 45:703-710.
• [94]Goedkoop AY, Kraan MC, Picavet DI, de Rie MA, Teunissen MB, Bos JD, Tak PP: Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy. Arthritis Res Ther 2004, 6:R326-R334. BioMed Central Full Text
• [95]Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, Nishimoto N: Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 2003, 48:1521-1529.
• [96]Szekanecz Z, Szücs G, Szántó S, Koch AE: Chemokines in rheumatic diseases. Curr Drug Target 2006, 7:91-102.
• [97]Szekanecz Z, Koch AE: Therapeutic inhibition of leukocyte recruitment in inflammatory diseases. Curr Opin Pharmacol 2004, 4:423-428.
• [98]Szekanecz Z, Koch AE: Vascular involvement in rheumatic diseases: 'vascular rheumatology'. Arthritis Res Ther 2008, 10:224. BioMed Central Full Text
• [99]Amat M, Benjamim CF, Williams LM, Prats N, Terricabras E, Beleta J, Kunkel SL, Godessart N: Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo. Br J Pharmacol 2006, 149:666-675.
• [100]Haringman JJ, Kraan MC, Smeets TJM, Zwinderman KH, Tak PP: Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann Rheum Dis 2003, 62:715-721.
• [101]Paniagua RT, Sharpe O, Ho PP, Chan SM, Chang A, Higgins JP, Tomooka BH, Thomas FM, Song JJ, Goodman SB, Lee DM, Genovese MC, Utz PJ, Steinman L, Robinson WH: Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 2006, 116:2633-2642.
• [102]Ando W, Hashimoto J, Nampei A, Tsuboi H, Tateishi K, Ono T, Nakamura N, Ochi T, Yoshikawa H: Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). J Bone Miner Metab 2006, 24:274-282.
• [103]Suzuki E, Umezawa K: Inhibition of macrophage activation and phagocytosis by a novel NF-kB inhibitor, dehydroxymethylepoxyquinomicin. Biomed Pharmacother 2006, 60:578-586.
• [104]Lainer-Carr D, Brahn E: Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Nat Clin Pract Rheumatol 2007, 3:434-442.
• [105]Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, Park JW: YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003, 95:516-525.
• [106]Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P: 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003, 3:363-375.